<DOC>
	<DOCNO>NCT00386061</DOCNO>
	<brief_summary>The primary objective ass effect SR141716 weight loss weight maintenance period one year prescribe hypocaloric diet obese patient without comorbidities . The main secondary objective assess effect SR141716 lipid parameter ( HDL-C , TG ) , glucose tolerance status , rate patient metabolic syndrome , waist circumference , glycemic parameter .</brief_summary>
	<brief_title>Rimonabant Obesity Over 2-Year Duration ( RIO-Europe )</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Rimonabant</mesh_term>
	<criteria>body mass index ( BMI ) e30 kg/m2 patient without comorbidities , BMI &gt; 27 kg/m2 patient treat untreated hypertension and/or treat untreated dyslipidemia . stable body weight ( variation &lt; 5 kg within 3 month prior screen visit ) ; History lowcalorie diet within 6 month prior screen visit ; history surgical procedure body weight loss ( eg , stomach stapling , bypass ) ; Presence clinically significant psychiatric , neurological endocrine disease Presence treat untreated type 1 type 2 diabetes ) ; SBP &gt; 165 mmHg and/or DBP &gt; 105 mmHg 2 consecutive visit screen inclusion visit ; History myocardial infarction unstable angina pectoris within 6 month prior screen visit ; history stroke within 6 month prior screen visit ; Administration antiobesity drug drug body weight reduction within 3 month prior screen visit ; The investigator evaluate whether reason patient may participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Obesity</keyword>
	<keyword>risk factor</keyword>
</DOC>